IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865), which tested…
An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases — has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone was achieved…
When Brenda Snow started experiencing vertigo, vision problems, and other symptoms in the early 1990s, she visited several doctors. However, as often happens with complex conditions, she struggled to have her concerns validated. Snow, who lived in Northern California at the time, didn’t give up. She continued looking for answers…
Discussion
There’s a bin of laundry in my car. It’s been there for days, but I keep putting off carrying it upstairs. My dryer is broken. It’s not a crisis, but it’s certainly inconvenient. It means I have to make a weekly trip to do laundry instead of running a load…
The Accelerated Cure Project for Multiple Sclerosis (ACP) has received funding to help interpret and share findings from the DISCO-MS study, which examined whether older adults with stable multiple sclerosis (MS) could stop disease-modifying medications, to support more informed treatment decisions. The award comes through the Eugene Washington…
Get regular updates to your inbox.
